Journal
DRUG DISCOVERY TODAY
Volume 24, Issue 1, Pages 112-128Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.drudis.2018.09.007
Keywords
-
Categories
Funding
- National Natural Science Foundation of China [81320108029, 81773995, 81573514, 81773827]
- Natural Science Foundation of Jiangsu Province [BK20151439]
- National Major Scientific and Technological Special Project [2015ZX09501004-002-004]
- Specific Fund for Public Interest Research of Traditional Chinese Medicine, Ministry of Finance [201507004-002]
- Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD)
- Higher Education Commission (HEC), Pakistan
Ask authors/readers for more resources
Bile acid (BA) has an important role in signal transduction, and has clinical applicability as an early biomarker for the diagnosis and prevention of cholestatic liver disease, which has a close relationship with BA homeostasis. Understanding the guarantee factors, function, and regulation of BA homeostasis under physiological conditions and in cholestatic liver diseases could provide novel therapeutic approaches for treating cholestatic liver injury. Here, we review potential biomarkers of BA, and new therapeutic approaches and the latest therapeutic drugs for cholestasis. We believe that the molecular mechanisms of cholestasis and the identification of key regulatory mechanisms of the enterohepatic circulation of BA could be pharmacologically targeted to cholestatic liver diseases.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
